Cedrulatinib | 2803

Cerdulatinib is a novel, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. It preferentially inhibits JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types. IL2 mediated STAT5 Y694 is inhibited with an IC₅₀ of 0.27 μM, while IL4 mediated signaling to STAT6 Y641 and functional responses in B cells and monocytes, namely CD69, CD25, and CD23 up-regulation, are inhibited with IC₅₀’s within the range of 0.11 μM to 0.57 μM.

Cerdulatinib is a novel, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. It preferentially inhibits JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types.

2803 | Cedrulatinib DataSheet

Alternate Name/Synonyms: 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide; PRT2070; PRT-2070; PRT 2070; PRT-062070; PRT 062070; PRT062070.

Appearance: White solid

Formulation: N/A

CAS Number: 1198300-79-6

Structure Available?: Y

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₀H₂₇N₇O₃S

Molecular Weight: 445.54

Cell-Permeable?: Y

Purity: ≥98% by HPLC

Solubilities: DMSO (>40 mg/ml)

Handling: Protect from light and moisture

Country of Origin: USA

Tag Line: A novel, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor

MDL Number: N/A

PubChem CID: 44595079

SMILES: CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N

InChi: nChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)

InChi Key: BGLPECHZZQDNCD-UHFFFAOYSA-N